Gouty Arthritis (Gout)-Pipeline Review, H1 2017

Gouty Arthritis (Gout)-Pipeline Review, H1 2017


  • Products Id :- GMDHC9369IDB
  • |
  • Pages: 95
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Gouty Arthritis (Gout)-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gouty Arthritis (Gout)-Pipeline Review, H1 2017, provides an overview of the Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline landscape.

Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gouty Arthritis (Gout)-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 11, 2, 16, 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) (Musculoskeletal Disorders).

The pipeline guide reviews pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Gouty Arthritis (Gout)-Overview

Gouty Arthritis (Gout)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Gouty Arthritis (Gout)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gouty Arthritis (Gout)-Companies Involved in Therapeutics Development

Allena Pharmaceuticals Inc

AstraZeneca Plc

C&C Research Laboratories

Cell Medica Ltd

CymaBay Therapeutics Inc

Genentech Inc

Immune Response BioPharma Inc

Jiangsu Hengrui Medicine Co Ltd

Monosol Rx LLC

Opsona Therapeutics Ltd

Polaris Pharmaceuticals Inc

Rigel Pharmaceuticals Inc

Swedish Orphan Biovitrum AB

Teijin Pharma Ltd

Wellstat Therapeutics Corp

XL-protein GmbH

Gouty Arthritis (Gout)-Drug Profiles

ALLN-346-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anakinra-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APP-112-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQB-565-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arhalofenate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

colchicine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dapansutrile-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diacerein-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diacerein CR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DLX-2323-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DLX-2681-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

febuxostat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSA-Uricase-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IR-888-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation, Neurodegenerative Diseases and Respiratory Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-2110-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-2158-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-346-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegadricase-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-191-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Enzyme for Gout and Tumor Lysis Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REV-002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RLBN-1001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-4640-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Gout-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GLUT9 for Gout-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TMX-049-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URC-102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

uriSHELS-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VCB-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

verinurad-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WT-2107-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XEN-102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-400-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gouty Arthritis (Gout)-Dormant Projects

Gouty Arthritis (Gout)-Discontinued Products

Gouty Arthritis (Gout)-Product Development Milestones

Featured News & Press Releases

Jan 11, 2017: First patient randomised in a phase II study evaluating safety and efficacy of anakinra in the treatment of acute gout

Jan 05, 2017: CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate

Dec 07, 2016: Selecta Presents Phase 1 Clinical Data for Lead Product Candidate, SEL-212, in Patients with Hyperuricemia at 11th Annual IMVAC Summit

Nov 13, 2016: Results of Study of Febuxostat on the Frequency of Acute Gout Flares in Early Gout

Oct 26, 2016: Selecta Biosciences Initiates Phase 2 Clinical Trial of SEL-212, First Non-Immunogenic Biologic in Development for Treatment of Gout

Jun 27, 2016: TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment

May 10, 2016: Revive Therapeutics Provides Clinical and Corporate Update

Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra)

Mar 28, 2016: CymaBay Therapeutics Announces Acceptance of Arhalofenate Phase 2b Gout Study Manuscript in Arthritis and Rheumatology

Mar 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra)

Jan 20, 2016: CymaBay Therapeutics Announces Successful Completion of End-of-Phase 2 Discussions With FDA for Arhalofenate

Dec 24, 2015: TWi Biotechnology Reports Positive Interim Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients

Dec 23, 2015: Selecta Biosciences Announces Dosing of First Patient in Phase 1b Clinical Trial of SEL-212, Designed to be the First Non-Immunogenic Biologic Treatment for Gout

Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6-11

Oct 19, 2015: MonoSol Rx Leadership Presents Data Supporting PharmFilm Technology Effective for Oral Peptide Delivery

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Gouty Arthritis (Gout), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Gouty Arthritis (Gout), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Gouty Arthritis (Gout)-Pipeline by Allena Pharmaceuticals Inc, H1 2017

Gouty Arthritis (Gout)-Pipeline by AstraZeneca Plc, H1 2017

Gouty Arthritis (Gout)-Pipeline by C&C Research Laboratories, H1 2017

Gouty Arthritis (Gout)-Pipeline by Cell Medica Ltd, H1 2017

Gouty Arthritis (Gout)-Pipeline by CymaBay Therapeutics Inc, H1 2017

Gouty Arthritis (Gout)-Pipeline by Genentech Inc, H1 2017

Gouty Arthritis (Gout)-Pipeline by Immune Response BioPharma Inc, H1 2017

Gouty Arthritis (Gout)-Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Gouty Arthritis (Gout)-Pipeline by Monosol Rx LLC, H1 2017

Gouty Arthritis (Gout)-Pipeline by Opsona Therapeutics Ltd, H1 2017

Gouty Arthritis (Gout)-Pipeline by Polaris Pharmaceuticals Inc, H1 2017

Gouty Arthritis (Gout)-Pipeline by Rigel Pharmaceuticals Inc, H1 2017

Gouty Arthritis (Gout)-Pipeline by Swedish Orphan Biovitrum AB, H1 2017

Gouty Arthritis (Gout)-Pipeline by Teijin Pharma Ltd, H1 2017

Gouty Arthritis (Gout)-Pipeline by Wellstat Therapeutics Corp, H1 2017

Gouty Arthritis (Gout)-Pipeline by XL-protein GmbH, H1 2017

Gouty Arthritis (Gout)-Dormant Projects, H1 2017

Gouty Arthritis (Gout)-Dormant Projects, H1 2017 (Contd..1), H1 2017

Gouty Arthritis (Gout)-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Allena Pharmaceuticals Inc, AstraZeneca Plc, C&C Research Laboratories, Cell Medica Ltd, CymaBay Therapeutics Inc, Genentech Inc, Immune Response BioPharma Inc, Jiangsu Hengrui Medicine Co Ltd, Monosol Rx LLC, Opsona Therapeutics Ltd, Polaris Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, Swedish Orphan Biovitrum AB, Teijin Pharma Ltd, Wellstat Therapeutics Corp, XL-protein GmbH

select a license
Single User License
USD 2000 INR 140000
Site License
USD 4000 INR 280000
Corporate User License
USD 6000 INR 420000

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com